Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

ID#: NCT04428788

Age: 18 years - 66+

Gender: Male

Healthy Subjects: No

Study Phase: Phase 1

Recruitment Status: Recruiting

Start Date: June 22, 2020

End Date: July 09, 2025

Contact Information:
BMS Study Connect Contact Center
First line of the email MUST contain the NCT# and Site #.
Summary: The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Inclusion Criteria:

- Must have histologically or cytologically confirmed adenocarcinoma of the prostate

- Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria:

- Prior treatment with an androgen receptor (AR) degrader

- Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP

- Clinically significant venous thromboembolism within 3 months prior to the first dose of IP

- Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply